Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Mr. Sean Brynjelsen is the President of Eton Pharmaceuticals Inc, joining the firm since 2017.
What is the price performance of ETON stock?
The current price of ETON is $23.84, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Eton Pharmaceuticals Inc?
Eton Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Eton Pharmaceuticals Inc market cap?
Eton Pharmaceuticals Inc's current market cap is $639.3M
Is Eton Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Eton Pharmaceuticals Inc, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell